5/6/2011

Novo Nordisk said degludec, an experimental long-acting insulin, proved superior to Sanofi-Aventis' best-seller Lantus in reducing hypoglycemia, particularly a nocturnal event, among patients with diabetes during a Phase IIIa trial. Novo Nordisk aims to market degludec and another formulation, degludec plus, during the first half of 2012.

Full Story:
Reuters

Related Summaries